NT-0796
General
Type : Not A\/B H target || Pro-Drug || Drug || Indacen || Pyrimidine
Chemical_Nomenclature : propan-2-yl (2R)-2-(1,2,3,5,6,7-hexahydro-s-indacen-4-ylcarbamoyloxy)-3-pyrimidin-2-ylpropanoate
Canonical SMILES : CC(C)OC(=O)C(CC1=NC=CC=N1)OC(=O)NC2=C3CCCC3=CC4=C2CCC4
InChI : InChI=1S\/C23H27N3O4\/c1-14(2)29-22(27)19(13-20-24-10-5-11-25-20)30-23(28)26-21-17-8-3-6-15(17)12-16-7-4-9-18(16)21\/h5,10-12,14,19H,3-4,6-9,13H2,1-2H3,(H,26,28)\/t19-\/m1\/s1
InChIKey : UMUQEMHROZVOTF-LJQANCHMSA-N
Other name(s) : S7V5RX5WBZ, SCHEMBL23139014, GTPL13008, EX-A8245
Target
Families : Carboxylesterase, Carb_B_Chordata
References (1)
| Title : Target cell activation of a structurally novel NLRP3 inhibitor NT-0796 enhances potency - Smolak_2024_J.Pharmacol.Exp.Ther__ |
| Author(s) : Smolak P , Nguyen M , Diamond C , Wescott H , Doedens JR , Schooley K , Snouwaert JN , Bock MG , Harrison D , Watt AP , Koller BH , Gabel CA |
| Ref : Journal of Pharmacology & Experimental Therapeutics , : , 2024 |
| Abstract : Smolak_2024_J.Pharmacol.Exp.Ther__ |
| ESTHER : Smolak_2024_J.Pharmacol.Exp.Ther__ |
| PubMedSearch : Smolak_2024_J.Pharmacol.Exp.Ther__ |
| PubMedID: 38253384 |